Congenica adds big hitter to help steer global scale-up and push into new therapy areas
Congenica, a digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, has appointed Dr Muthu Meyyappan as chief commercial officer.
Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Cambridge, UK-headquartered Congenica has a global footprint supporting leading international laboratories, academic medical centres and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
Dr Meyyappan will lead all aspects of Congenica’s sales and marketing and will be based in Boston, MA.
His appointment follows the company’s blistering $50m Series C funding round which will enable the acceleration of global market development and further expansion into new therapy areas.
Dr Meyyappan has more than 20 years of international experience building and leading diverse, global teams spanning sales, marketing and customer support for companies within genomics, clinical informatics, and software.
He served as chief commercial officer for Variantyx where he was responsible for the overall commercial strategy for the company’s whole genome testing services for rare disease diagnosis marketed to clinicians and hospitals.
Previously, he was the VP of advanced genomics commercial operations for QIAGEN. He was also chief business officer for BIOBASE GmbH and held senior roles at Incyte Genomics.
Congenica CEO, Dr David Atkins, said: “Muthu has highly impressive credentials with significant global sales and marketing experience which will make him a real asset to the Congenica team. It is a pleasure to welcome him to the business as we utilise our product platform for new indications including somatic cancer and wellness and continue to enter new markets.”
Dr Meyyappan added: “Congenica is highly regarded in the genomics field and it is exciting to join at this stage of the company’s development. I look forward to working with the rest of the management as the business scales up international expansion and diversifies into new therapy areas.”